Mucositis: Pathobiology and management

Current Opinion in Oncology

Volumn 27, Issue 3, 2015, Pages 159-164

  Villa, Alessandro ^a,b   Sonis, Stephen T ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

cancer; mucositis; supportive care

Indexed keywords

ACETYLCYSTEINE; AMIFOSTINE; ANTIINFLAMMATORY AGENT; AVX 470; BENZYDAMINE; BIOLOGICAL PRODUCT; BRILACIDIN; CLAZAKIZUMAB; CLONIDINE; DOXEPIN; FILGRASTIM; FLUOROURACIL; GLIAMILIDE; MOUTHWASH; NEW DRUG; PALIFERMIN; PENTOXIFYLLINE; POLYCLONAL ANTIBODY; REGENASYN; RTA 401; SARGRAMOSTIM; SGX 942; UNCLASSIFIED DRUG; VELAFERMIN; ANTINEOPLASTIC AGENT; KERATINOCYTE GROWTH FACTOR; RADIOPROTECTIVE AGENT;

CHEMORADIOTHERAPY; DISEASE SEVERITY; GENETIC ASSOCIATION; GENETIC RISK; HIGH RISK PATIENT; HUMAN; LOW LEVEL LASER THERAPY; MICROBIOME; MOUTH HYGIENE; MUCOSA INFLAMMATION; NONHUMAN; ORAL MUCOSITIS; PALLIATIVE THERAPY; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; TREATMENT PLANNING; ADVERSE DRUG REACTION; ADVERSE EFFECTS; CHEMICALLY INDUCED; COMPLICATION; NEOPLASMS; POST EXPOSURE PROPHYLAXIS; STOMATITIS;

AMIFOSTINE; ANTINEOPLASTIC AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FIBROBLAST GROWTH FACTOR 7; HUMANS; NEOPLASMS; POST-EXPOSURE PROPHYLAXIS; QUALITY OF LIFE; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY; RISK FACTORS; STOMATITIS;

EID: 84928496512     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000180     Document Type: Review

References (49)

1. Sonis ST. Oral mucositis in head and neck cancer: risk, biology, and management. Am Soc Clin Oncol Educ Book 2013.
2. Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2014; 120:1453-1461.
3. Al-Dasooqi N, Sonis ST, Bowen JM, et al. Emerging evidence on the pathobiology of mucositis. Supportive Care Cancer 2013; 21:2075-2083.
4. Nomura M, Kamata M, Kojima H, et al. Irsogladine maleate reduces the incidence of fluorouracil-based chemotherapy-induced oral mucositis. Ann Oncol 2013; 24:1062-1066.
5. Lalla RV, Sonis ST, Peterson DE. Management of oral mucositis in patients who have cancer. Dent Clin North Am 2008; 52:61-77.
6. Sonis ST, Eilers JP, Epstein JB, et al. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group. Cancer 1999; 85:2103-2113.
7. Sonis ST. Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol 2007; 5 (9 Suppl 4):3-11.
8. Murphy BA. Clinical and economic consequences of mucositis induced by chemotherapy and/or radiation therapy. J Support Oncol 2007; 5 (9 Suppl 4):13-21.
9. Mortensen HR, Overgaard J, Specht L, et al. Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer. Radiother Oncol 2012; 103:69-75.
10. Keefe DM, Schubert MM, Elting LS, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007; 109:820-831.
11. Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004; 100 (9 Suppl):1995-2025.
12. Blijlevens N, Schwenkglenks M, Bacon P, et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy - European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 2008; 26:1519-1525.
13. Bensinger W, Schubert M, Ang KK, et al. NCCN Task Force Report. Prevention and management of mucositis in cancer care. J Natl Compr Canc Netw 2008; 6 (Suppl 1):S1-S21.
14. Chansky K, Benedetti J, Macdonald JS. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer 2005; 103:1165-1171.
15. Filippi AR, Franco P, Ricardi U. Is clinical radiosensitivity a complex genetically controlled event? Tumori 2006; 92:87-91.
16. Peterson DE, Keefe DM, Sonis ST. New frontiers in mucositis. Am Soc Clin Oncol Educ Book 2012; 545-551.
17. Sonis S, Haddad R, Posner M, et al. Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. Oral Oncol 2007; 43:289-300.
18. Logan RM, Stringer AM, Bowen JM, et al. Serum levels of NFkappaB and proinflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther 2008; 7:1139-1145.
19. Ong ZY, Gibson RJ, Bowen JM, et al. Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat Oncol 2010; 5:22.
20. Murphy CK, Fey EG, Watkins BA, et al. Efficacy of superoxide dismutase mimetic M40403 in attenuating radiation-induced oral mucositis in hamsters. Clin Cancer Res 2008; 14:4292-4297.
21. Pratesi N, Mangoni M, Mancini I, et al. Association between single nucleotide polymorphisms in the XRCC1 and RAD51 genes and clinical radiosensitivity in head and neck cancer. Radiother Oncol 2011; 99:356-361.
22. Sonis S, Antin J, Tedaldi M, Alterovitz G. SNP-based Bayesian networks can predict oral mucositis risk in autologous stem cell transplant recipients. Oral Dis 2013; 19:721-727.
23. Coleman EA, Lee JY, Erickson SW, et al. GWAS of 972 autologous stem cell recipients with multiple myeloma identifies 11 genetic variants associated with chemotherapy-induced oral mucositis. Support Care Cancer 2015; 23:841-849.
24. Bogunia-Kubik K, Mazur G, Urbanowicz I, et al. Lack of association between the TNF-alpha promoter gene polymorphism and susceptibility to B-cell chronic lymphocytic leukaemia. Int J Immunogenet 2006; 33:21-24.
25. Sonis ST. Mucositis: the impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol 2009; 45:1015-1020.
26. Sonis ST. The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with antineoplastic therapy. Crit Rev Oral Biol Med 2002; 13:380-389.
27. Logan RM, Gibson RJ, Sonis ST, Keefe DM. Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol 2007; 43:395-401.
28. Logan RM, Gibson RJ, Bowen JM, et al. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol 2008; 62:33-41.
29. Logan RM, Stringer AM, Bowen JM, et al. The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev 2007; 33:448-460.
30. Djuric M, Hillier-Kolarov V, Belic A, Jankovic L. Mucositis prevention by improved dental care in acute leukemia patients. Support Care Cancer 2006; 14:137-146.
31. Nicolatou-Galitis O, Sarri T, Bowen J, et al. Systematic review of amifostine for the management of oral mucositis in cancer patients. Support Care Cancer 2013; 21:357-364.
32. Moslehi A, Taghizadeh-Ghehi M, Gholami K, et al. N-acetyl cysteine for prevention of oral mucositis in hematopoietic SCT: a double-blind, randomized, placebo-controlled trial. Bone Marrow Transplant 2014; 49:818-823.
33. Keefe DM, Sonis ST, Bowen JM. Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs 2008; 13:511-522.
34. Yuan A, Sonis S. Emerging therapies for the prevention and treatment of oral mucositis. Expert Opin Emerg Drugs 2014; 19:343-351.
35. Sonis S, Watkins E, Yuschak M, Parenti D. Mechanism of action of benzydamine in the treatment of oral mucositis. J Clin Oncol 2005; 23:8040.
36. Nicolatou-Galitis O, Sarri T, Bowen J, et al. Systematic review of antiinflammatory agents for the management of oral mucositis in cancer patients. Support Care Cancer 2013; 21:3179-3189.
37. Melo ML, Brito GA, Soares RC, et al. Role of cytokines (TNF-alpha, IL-1beta and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide. Cancer Chemother Pharmacol 2008; 61:775-784.
38. Ferra C, de Sanjose S, Lastra CF, et al. Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications. Bone Marrow Transplant 1997; 20:1075-1080.
39. Sonis ST, Peterson RL, Edwards LJ, et al. Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol 2000; 36:373-381.
40. Lopes NN, Plapler H, Chavantes MC, et al. Cyclooxygenase-2 and vascular endothelial growth factor expression in 5-fluorouracil-induced oral mucositis in hamsters: evaluation of two low-intensity laser protocols. Support Care Cancer 2009; 17:1409-1415.
41. Oberoi S, Zamperlini-Netto G, Beyene J, et al. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. PLoS One 2014; 9:e107418.
42. Basso FG, Oliveira CF, Kurachi C, et al. Biostimulatory effect of low-level laser therapy on keratinocytes in vitro. Lasers Med Sci 2013; 28:367-374.
43. Kujawa J, Zavodnik L, Zavodnik I, et al. Effect of low-intensity (3.75-25 J/cm2) near-infrared (810 nm) laser radiation on red blood cell ATPase activities and membrane structure. J Clin Laser Med Surg 2004; 22:111-117.
44. Allison RR, Ambrad AA, Arshoun Y, et al. Multiinstitutional, randomized, double-blind, placebo-controlled trial to assess the efficacy of a mucoadhesive hydrogel (MuGard) in mitigating oral mucositis symptoms in patients being treated with chemoradiation therapy for cancers of the head and neck. Cancer 2014; 120:1433-1440.
45. Buchsel PC. Polyvinylpyrrolidone-sodium hyaluronate gel (Gelclair): a bioadherent oral gel for the treatment of oral mucositis and other painful oral lesions. Expert Opin Drug Metab Toxicol 2008; 4:1449-1454.
46. Quinn B. Efficacy of a supersaturated calcium phosphate oral rinse for the prevention and treatment of oral mucositis in patients receiving high-dose cancer therapy: a reviewof current data. Eur JCancer Care2013; 22:564-579.
47. Raphael MF, den Boer AM, Kollen WJ, et al. Caphosol, a therapeutic option in case of cancer therapy-induced oral mucositis in children? Results from a prospective multicenter double blind randomized controlled trial. Supportive Care Cancer 2014; 22:3-6.
48. Dodd MJ, Dibble SL, Miaskowski C, et al. Randomized clinical trial of the effectiveness of 3 commonly used mouthwashes to treat chemotherapyinduced mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 90:39-47.
49. Han G, Bian L, Li F, et al. Preventive and therapeutic effects of Smad7 on radiation-induced oral mucositis. Nat Med 2013; 19:421-428.